CPA 926

CPA 926 is a prodrug of Esculetin (HY-N0284) and is orally active. CPA 926 can inhibit the production of MMP in cartilage explants. CPA 926 can be used for the research of inflammation, such as experimental osteoarthritis[1].

Product Specifications

CAS Number

[169673-60-3]

UNSPSC

12352005

Target

MMP

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Inflammation/Immunology

Smiles

OC1=C(C=C2C(OC(C=C2)=O)=C1)O[C@H]3[C@@H]([C@H]([C@H](O)[C@@H](CO)O3)O)NC(C)=O

Molecular Formula

C17H19NO9

Molecular Weight

381.33

References & Citations

[1]Yamada H, et al. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol. 1999 Mar;26 (3) :654-62.